Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐<scp>PD1</scp> Therapy
In this cohort, nearly half of the patients underwent recurrences and RFS at 24 months was 64%. The RFS and OS data were comparable o those reported in the pivotal study Ulceration was the only significant predictive factor for recurrence, associated with decreased RFS at 24 months.
Authors
- S. Idoudi (ORCID: https://orcid.org/0000-0001-6285-5176)
- S. Milley
- Stéphane Dalle (ORCID: https://orcid.org/0000-0002-3423-4548)
- Nicolas Romain‐Scelle (ORCID: https://orcid.org/0000-0002-9036-411X)
- Anaïs Eberhardt (ORCID: https://orcid.org/0009-0006-6099-554X)
- L. Thomas (ORCID: https://orcid.org/0000-0003-1995-2434)
- Liza Benzoni
- Camille Trefcon
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Hospices Civils de Lyon (FR)
- Centre Léon Bérard (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Hôpital Saint-Louis (FR)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cam4.70432
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00